Literature DB >> 22882342

From Severe Combined Immunodeficiency to Omenn syndrome after hematopoietic stem cell transplantation in a RAG1 deficient family.

Laura Martinez-Martinez1, Marta Vazquez-Ortiz, Cecilia Gonzalez-Santesteban, Andrea Martin-Nalda, Asunción Vicente, Ana M Plaza, Isabel Badell, Laia Alsina, Oscar de la Calle-Martin.   

Abstract

BACKGROUND: Mutations in RAG genes cause a spectrum of severe immunodeficiencies ranging from Severe Combined Immunodeficiency (SCID) T-B-NK+ to Omenn syndrome (OS) through intermediate phenotypes, even for the same alteration. Nowadays, hematopoietic stem cell transplantation (HSCT) is the unique curative treatment available.
METHODS: We describe three related patients from a Moroccan consanguineous family. Patient 1 developed at 1 month of age moderate eczematous dermatitis with eosinophilia, followed by infections and enteritis. He was transplanted and received reduced intensity conditioning regimen previous to HSCT. His brother, patient 2, was born preterm with a severe neonatal erythroderma, hepatosplenomegaly and lymphadenopathy. Patient 3, cousin of the two siblings, was also born preterm and fulfilled all criteria for classical OS. Immunological evaluation was performed and RAG genes were sequenced.
RESULTS: Immunological data from all three patients were very diversed, from T lymphopenia to marked lymphocytosis, and different degrees of eosinophilia and IgE levels. Non-responder T cells and absent B cells were constant. All patients presented the same homozygous mutation in RAG1 gene (c.631delT). Patient 1 fully recovered both clinically and immunologically after HSCT. Two years later, he lost the accomplished lymphoid chimera and the disease relapsed as a classical OS, leading to patient's death.
CONCLUSIONS: This is the first report of a RAG1 deficient patient with a changed clinical and immunological phenotype from SCID to OS after HSCT. The use of a myeloablative conditioning regimen that eliminates reminiscent T cells might have improved patient's outcome and it should be considered in similar cases.
© 2012 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22882342     DOI: 10.1111/j.1399-3038.2012.01339.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  4 in total

1.  Clinical, immunologic, and genetic characteristics of RAG mutations in 15 Chinese patients with SCID and Omenn syndrome.

Authors:  Xiaoming Bai; Jing Liu; Zhiyong Zhang; Chaohong Liu; Yongjie Zhang; Wenjing Tang; Rongxin Dai; Junfeng Wu; Xuemei Tang; Yu Zhang; Yuan Ding; Liping Jiang; Xiaodong Zhao
Journal:  Immunol Res       Date:  2016-04       Impact factor: 4.505

Review 2.  Lessons from Genetic Studies of Primary Immunodeficiencies in a Highly Consanguineous Population.

Authors:  Mohamed-Ridha Barbouche; Najla Mekki; Meriem Ben-Ali; Imen Ben-Mustapha
Journal:  Front Immunol       Date:  2017-06-27       Impact factor: 7.561

3.  Mutation c.256_257delAA in RAG1 Gene in Polish Children with Severe Combined Immunodeficiency: Diversity of Clinical Manifestations.

Authors:  Anna Szaflarska; Magdalena Rutkowska-Zapała; Monika Kotula; Anna Gruca; Agnieszka Grabowska; Marzena Lenart; Marta Surman; Elżbieta Trzyna; Anna Mordel; Anna Pituch-Noworolska; Maciej Siedlar
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2017-01-12       Impact factor: 4.291

4.  Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes.

Authors:  Hanna IJspeert; Gertjan J Driessen; Michael J Moorhouse; Nico G Hartwig; Beata Wolska-Kusnierz; Krzysztof Kalwak; Anna Pituch-Noworolska; Irina Kondratenko; Joris M van Montfrans; Ester Mejstrikova; Arjan C Lankester; Anton W Langerak; Dik C van Gent; Andrew P Stubbs; Jacques J M van Dongen; Mirjam van der Burg
Journal:  J Allergy Clin Immunol       Date:  2014-01-11       Impact factor: 10.793

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.